AUROPHARMA.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 09:48):

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India...

Stats
Šios dienos apimtis	943 107
Vidutinė apimtis	2.61M
Rinkos kapitalizacija	673.95B
EPS	INR0 ( 2024-02-11 )
Kita pelno data	( INR14.00 ) 2024-05-25
Last Dividend	INR3.00 ( 2023-02-17 )
Next Dividend	INR0 ( N/A )
P/E	24.32
ATR14	INR1.198 (0.10%)

Tūris Koreliacija

Ilgas: 0.37 (neutral)

Trumpas: -0.67 (moderate negative)

Signal:(53.19) Neutral

Aurobindo Pharma Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SETF10GILT.NS	0.946
IZMO.NS	0.936
ADORWELD.NS	0.933
ANMOL.NS	0.927
GTNTEX.NS	0.92
ANURAS.NS	0.918
FOCUS.NS	0.918
TIIL.NS	0.917
GISOLUTION.NS	0.914
KIRLOSIND.NS	0.913

10 Labiausiai neigiamai susiję koreliacijos
STARTECK.NS	-0.883
GENESYS.NS	-0.878
EASTSILK.NS	-0.871
SEYAIND.NS	-0.871
ORTINLAB.NS	-0.864
DEEPINDS.NS	-0.862
GRMOVER.NS	-0.859
KOHINOOR.NS	-0.856
CLNINDIA.NS	-0.853
ESABINDIA.NS	-0.852

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Aurobindo Pharma Limited Koreliacija - Valiuta/Žaliavos

0.33
( neutral )

0.15
( neutral )

0.46
( neutral )

0.67
( moderate )

0.10
( neutral )

-0.63
( weak negative )

Aurobindo Pharma Limited Finansinės ataskaitos

Annual	2022
Pajamos:	INR246.17B
Bruto pelnas:	INR133.24B (54.12 %)
EPS:	INR32.90

FY	2022
Pajamos:	INR246.17B
Bruto pelnas:	INR133.24B (54.12 %)
EPS:	INR32.90

FY	2022
Pajamos:	INR233.67B
Bruto pelnas:	INR132.26B (56.60 %)
EPS:	INR45.19

FY	2021
Pajamos:	INR245.58B
Bruto pelnas:	INR146.55B (59.68 %)
EPS:	INR91.05

Financial Reports:

No articles found.

Aurobindo Pharma Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR3.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Aurobindo Pharma Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.12 - low (37.00%) | Divividend Growth Potential Score: 3.14 - Decrease likely (37.25%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.150	2001-09-12
Last Dividend	INR3.00	2023-02-17
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	42	--
Total Paid Out	INR38.23	--
Avg. Dividend % Per Year	0.47%	--
Score	2.7	--
Div. Sustainability Score	4.12
Div.Growth Potential Score	3.14
Div. Directional Score	3.63	--

Next Divdend (Est)
(2024-10-01)

INR0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

2.70

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR2.25	0.36%
2019	INR2.50	0.34%
2020	INR4.25	0.93%
2021	INR4.50	0.49%
2022	INR6.00	0.82%
2023	INR3.00	0.69%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
UBL.NS	Dividend Junior	2023-08-03	Annually	17	0.27%
POLYCAB.NS	Dividend Knight	2023-06-21	Annually	6	0.50%
JSL.NS	Dividend Junior	2023-09-15	Sporadic	22	0.26%
DLF.NS	Dividend Junior	2023-07-28	Annually	18	0.60%
AARON.NS	Dividend Junior	2023-08-28	Sporadic	5	0.36%
SOUTHBANK.NS	Dividend Junior	2023-08-17	Sporadic	25	0.42%
MONARCH.NS	Dividend Junior	2023-09-14	Annually	3	0.20%
HERANBA.NS	Dividend Junior	2023-08-17	Annually	4	0.20%
BHEL.NS	Dividend Junior	2023-08-11	Annually	21	0.26%
RAMCOIND.NS	Dividend Junior	2023-08-02	Annually	23	0.32%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.100	1.500	7.99	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.101	1.500	9.99	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	15.99	1.000	5.19	5.19	[3 - 30]
operatingCashFlowPerShareTTM	51.10	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	25.58	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.548	1.000	4.20	4.20	[0.2 - 0.8]
operatingProfitMarginTTM	0.148	1.000	9.03	9.03	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.12

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	23.93	1.000	7.68	0	[1 - 100]
returnOnEquityTTM	0.101	2.50	10.00	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	25.58	2.00	1.474	10.00	[0 - 30]
dividendYielPercentageTTM	0.398	1.500	0.0557	0	[0 - 0.4]
operatingCashFlowPerShareTTM	51.10	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.413	1.500	-6.08	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.109	1.000	9.79	0	[0.1 - 0.5]
Total Score				3.14

Aurobindo Pharma Limited

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.